| 2025-02-12 | +0.38 % |
|
| 2025-02-10 | -2.32 % |
|
| 2025-02-07 | -0.99 % |
|
| 2025-02-06 | -3.84 % |
|
| 2025-02-05 | +1 % |
|
| 2025-02-04 | -1.38 % |
|
| 2025-02-03 | +1.7 % |
|
| 2025-01-30 | +0.15 % |
|
| 2025-01-29 | +0.49 % |
|
| 2025-01-24 | +0.9 % |
|
| 2025-01-23 | +3.59 % |
|
| 2025-01-22 | +0.09 % |
|
| 2025-01-17 | -0.16 % |
|
| 2025-01-15 | +0.3 % |
|
| 2025-01-10 | -1.73 % |
|
| 2025-01-06 | +0.19 % |
|
| 2025-01-03 | -0.39 % |
|
| 2025-01-02 | +0.41 % |
|
| 2024-12-27 | -0.55 % |
|
| 2024-12-19 | -0.95 % |
|
| 2024-12-18 | -1.41 % |
|
| 2024-12-17 | +3.19 % |
|
| 2024-12-16 | +0.16 % |
|
| 2024-12-10 | -1 % |
|
| 2024-12-09 | -1.13 % |
|
| 2024-12-02 | +1.22 % |
|
| 2024-11-27 | +0.9 % |
|
| 2024-11-26 | -0.07 % |
|
| 2024-11-25 | -0.15 % |
|
| 2024-11-22 | +1.1 % |
|
| 2024-11-21 | +0.6 % |
|
| 2024-11-20 | -0.6 % |
|
| 2024-11-19 | +2.52 % |
|
| 2024-11-18 | +1.03 % |
|
| 2024-11-15 | -3.9 % |
|
| 2024-11-12 | -1.34 % |
|
| 2024-11-11 | +10.49 % |
|
| 2024-11-08 | -1.04 % |
|
| 2024-11-07 | -1.03 % |
|
| 2024-11-05 | +0.9 % |
|
| 2024-11-04 | +2.08 % |
|
| 2024-10-31 | +5.91 % |
|
| 2024-10-30 | +0.3 % |
- Bristol Myers Squibb (BMY) stock experienced a 0.3% increase, likely due to positive investor sentiment or developments in its collaborations, particularly with companies such as Exscientia, which is involved in innovative drug development targeting high unmet medical needs.
- Bristol-Myers Squibb (BMY) stock rose 0.3% due to increased institutional investment, positive analyst reports raising price targets, and the announcement of a quarterly dividend.
- Bristol-Myers Squibb (BMY) stock rose 0.3% as institutional investors, despite some reducing their positions, showed continued interest, with new acquisitions made by others, alongside positive analyst ratings and a solid dividend announcement.
- Bristol-Myers Squibb (BMY) stock rose 0.3% last night amid a consensus "Reduce" recommendation from analysts, with factors such as active buying from hedge funds and upcoming dividends contributing to the stock's uptick.
|
| 2024-10-29 | -0.27 % |
|
| 2024-10-28 | +1.39 % |
|
| 2024-10-25 | -1.89 % |
|
| 2024-10-24 | -0.26 % |
|
| 2024-10-23 | +0.57 % |
|
| 2024-10-22 | +1.23 % |
|
| 2024-10-21 | -2.07 % |
|
| 2024-10-17 | -0.36 % |
|
| 2024-10-16 | +1.16 % |
|
| 2024-10-15 | +0.17 % |
|
| 2024-10-14 | +0.9 % |
|
| 2024-10-11 | -0.38 % |
|
| 2024-10-10 | -0.76 % |
|
| 2024-10-09 | +0.61 % |
|
| 2024-10-08 | -1.8 % |
|
| 2024-10-07 | -0.96 % |
|
| 2024-10-03 | +0.82 % |
|
| 2024-10-02 | +1.63 % |
|
| 2024-10-01 | +2.24 % |
|
| 2024-09-30 | +1.63 % |
|
| 2024-09-27 | +1.58 % |
- Bristol Myers Squibb (BMY) stock increased by 1.58% following the FDA's approval of its innovative schizophrenia treatment, Cobenfy, marking a significant advancement in therapies for the condition. The stock rose due to the expected impact of the new drug, which represents a fundamentally different treatment approach and addresses a significant need in the market for effective schizophrenia therapies.
- Bristol Myers Squibb (BMY) stock rose by 1.58% following the FDA's approval of its new schizophrenia drug, which is expected to have fewer side effects than existing treatments.
- Bristol Myers Squibb (BMY) stock rose 1.58% following the FDA's approval of its new schizophrenia treatment, Cobenfy, which introduces a novel pharmacological approach and has significant potential for changing the treatment landscape for the estimated 2.8 million affected individuals in the U.S.
The stock went up due to the positive market reaction to the FDA approval of Cobenfy, which is seen as a major advancement in schizophrenia treatment and may enhance Bristol Myers Squibb's revenue prospects.
- Bristol Myers Squibb's stock rose 1.58% following the FDA's approval of their new schizophrenia drug, Cobenfy, which represents a significant advancement in treatment options for the disorder and is projected to generate substantial sales.
- Bristol Myers Squibb's (BMY) stock rose by 6% following the FDA's approval of its schizophrenia drug, which offers patients a treatment option that alleviates symptoms without common side effects.
|
| 2024-09-26 | +0.34 % |
|
| 2024-09-25 | -1.94 % |
|
| 2024-09-24 | +1.86 % |
|
| 2024-09-16 | +1.75 % |
|
| 2024-09-12 | -0.72 % |
|
| 2024-09-10 | +1.61 % |
|
| 2024-09-09 | -0.41 % |
|
| 2024-09-05 | -0.32 % |
|
| 2024-09-03 | +1.14 % |
|
